Off-label use of novel drugs in paediatric oncology is inconsistently documented, results in objective response in a majority of patients but ultimately fails to impact survival, an Australian study shows. A retrospective audit of practice at a tertiary paediatric oncology centre in Melbourne between 2010 and 2019 has identified 100 patients prescribed 133 drugs across ...
‘Try anything’ off-label approach in childhood cancer under the microscope
By Mardi Chapman
10 May 2021